HDAX Therapeutics

HDAX Therapeutics is a small molecule preclinical stage drug discovery company that emerged from Dr. Patrick Gunning’s group at the University of Toronto. We are developing targeted therapeutics for the treatment of brain cancers and neurodegenerative disorders, by selectively targeting the disease driver protein HDAC6 in the brain. For these unmet needs that have no…